Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;16(4):815-830.
doi: 10.1007/s11739-020-02616-5. Epub 2021 Jan 16.

A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations

Affiliations
Review

A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations

Arunkumar Krishnan et al. Intern Emerg Med. 2021 Jun.

Abstract

Coronavirus disease 2019 (COVID-19) is an emerging infectious disease which has had a rapid surge in cases and deaths since it is first documented in Wuhan, China, in December 2019. COVID-19 is caused by the Betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 uses angiotensin-converting enzyme 2, which is highly expressed in the human lower respiratory tract but also in other tissues, as the cellular entry receptor. Thus, COVID-19 mainly affects the respiratory system but can cause damage to other body systems, including the cardiovascular, gastrointestinal, hepatobiliary, renal, and central nervous systems. We review the pathogenesis and clinical manifestations of the infection, focusing on our current understanding of the disease mechanisms and their translation to clinical outcomes, as well as adverse effects on different body systems. We also discuss the epidemiology pathogenesis, clinical, and multi-organ consequences, and highlight some of the research gaps regarding COVID-19.

Keywords: COVID-19; Clinical symptoms; Coronavirus; Epidemiology; SARS-CoV-2; Transmission.

PubMed Disclaimer

Conflict of interest statement

All the authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Pathogenesis and the interaction of the viral spike (S)-protein with angiotensin-converting enzyme 2 receptor (ACE2): (1) S proteins on the surface of
Fig. 2
Fig. 2
Gastrointestinal symptoms in patients with COVID-19

Similar articles

Cited by

References

    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19.Online: https://www.who.int/dg/speeches/detail/whodirector- general-s-opening-remarks-at-the-media-briefing-on-covid-19. Accessed 14 Aug 2020
    1. Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–544. doi: 10.1038/s41564-020-0695-z. - DOI - PMC - PubMed
    1. Novel Coronavirus (2019-nCoV) Situation Report – 22 (World Health Organization); https://www.who.int/docs/default-source/coronaviruse/situation-reports/2.... Accessed 14 Aug 2020
    1. . World Health Organization. Summary of probable SARS cases with onset of illness Geneva (Switzerland): World Health Organization; 2003 Dec. Available from: https://www.who.int/csr/sars/country/table2004_04_21/en. Accessed 14 Aug 2020